The initiative will target diseases such as endometriosis, polycystic ovary syndrome, triple-negative breast cancer, or ovarian cancer, according to the companies. Auransa will utilize its SMarTR Engine predictive computational software and make use of a pipeline of novel compounds for various diseases.

For its part, Polaris will provide its Tachyon drug discovery platform, which scans billions of molecules from a large chemical space to find novel molecular drugs, the companies said.

COVID-19 therapies could come from existing drugs
At least four drugs that have already been approved by the U.S. Food and Drug Administration may be effective as COVID-19 therapies, according to a study...

GNS to develop computer model for prostate cancer
GNS Healthcare has announced plans to develop and launch an in silico digital patient called Gemini to help determine responses to treatment for developers...

Eikon raises $148M for super-res microscopy-aided drug discovery
Eikon Therapeutics has closed $148 million in financing to integrate engineering, advanced optics, and machine learning into its super-resolution...

What pregnant women need to know about COVID vaccines
Addressing questions about COVID-19 vaccines for pregnant and postpartum women, a leading maternal-fetal medicine specialist explained that it's likely...

EPA launches Women in Radiation History website
The U.S. Environmental Protection Agency (EPA) is marking Women's History Month with the launch of a new website to celebrate the history of women in...